Protara Therapeutics with ticker code (TARA) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 50 and 37 with a mean TP of 45.67. Given that the stocks previous close was at 24.68 this now indicates there is a potential upside of 85.0%. The day 50 moving average is 22.35 and the 200 day MA is 23.42. The market capitalisation for the company is $258m. You can visit the company’s website by visiting: http://www.protaratx.com
The potential market cap would be $477m based on the market concensus.
Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics and changed its name to Protara Therapeutics in May 2020. Protara Therapeutics is based in New York, New York.
